Henri Spronk

Associate professor

Initially trained in Biochemistry and Molecular Biology at Nijmegen University, Dr Henri Spronk obtained a PhD in Biochemistry on the effects of impaired vitamin K-dependent protein carboxylation.

The focus of his current work is on the bidirectional relation between coagulation and inflammation, as well as on the applicability of functional plasma assays such as thrombin generation, for atherothrombotic risk prediction. He has a special interest in the role of active coagulation factors, mainly thrombin, in activation of protein-activated receptors (PARs) which can regulate the balance between vascular protective and disruptive. Overall, knowledge on the non-haemostatic functions of thrombin and factor Xa enables pharmacological interference in cellular processes contributing to the the development and progression of atherosclerosis or atrial fibrillation.

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.326
T: +31(0)43 388 42 61

  • 2022
    • Willems, L. H., Thijssen, D. H. J., Groh, L. A., Kooijman, N. I., Ten Cate, H., Spronk, H. M. H., Donders, A. R. T., Van der Vijver-Coppen, R. J., van Hoek, F., Nagy, M., Reijnen, M. M. P. J., & Warle, M. C. (2022). Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial. Frontiers in cardiovascular medicine, 9, [979819]. https://doi.org/10.3389/fcvm.2022.979819
    • van de Berg, T. W., Mulder, M. M. G., Alnima, T., Nagy, M., van Oerle, R., Beckers, E. A. M., Hackeng, T. M., Hulshof, A. M., Sels, J. W. E. M., Henskens, Y. M. C., van der Horst, I. C. C., ten Cate, H., Spronk, H. M. H., van Bussel, B. C. T., & Dutch COVID & Thrombosis Coalition (2022). Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort. Frontiers in cardiovascular medicine, 9, [929284]. https://doi.org/10.3389/fcvm.2022.929284
    • van Paridon, P. C. S., Panova-Noeva, M., van Oerle, R., Schulz, A., Prochaska, J. H., Arnold, N., Schmidtmann, I., Beutel, M., Pfeiffer, N., Munzel, T., Lackner, K. J., ten Cate, H., Wild, P. S., & Spronk, H. M. H. (2022). Lower levels of vWF are associated with lower risk of cardiovascular disease. Research and practice in thrombosis and haemostasis, 6(7), [e12797]. https://doi.org/10.1002/rth2.12797
    • Bochenek, M. L., Gogiraju, R., Grossmann, S., Krug, J., Orth, J., Reyda, S., Georgiadis, G. S., Spronk, H. M., Konstantinides, S., Munzel, T., Griffin, J. H., Wild, P., Espinola-Klein, C., Ruf, W., & Schafer, K. (2022). EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia. JCI INSIGHT, 7(14). https://doi.org/10.1172/jci.insight.157701
    • Robles, A. P., ten Cate, V., Schulz, A., Prochaska, J. H., Rapp, S., Koeck, T., Panova-Noeva, M., Heitmeier, S., Schwers, S., Leineweber, K., Seyfarth, H. J., Opitz, C. F., Spronk, H., Espinola-Klein, C., Lackner, K. J., Munzel, T., Andrade-Navarro, M. A., Konstantinides, S. V., ten Cate, H., & Wild, P. S. (2022). Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Scientific Reports, 12(1), [9761]. https://doi.org/10.1038/s41598-022-13174-5
    • van Paridon, P. C. S., Panova-Noeva, M., van Oerle, R., Schulz, A., Prochaska, J. H., Arnold, N., Schmidtmann, I., Beutel, M., Pfeiffer, N., Münzel, T., Lackner, K. J., Ten Cate, H., Wild, P. S., & Spronk, H. M. H. (2022). Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background. Thrombosis Journal, 20(1), [32]. https://doi.org/10.1186/s12959-022-00392-0
    • Dolleman, S. C., Agten, S. M., Spronk, H. M. H., Hackeng, T. M., Bos, M. H. A., Versteeg, H. H., van Zonneveld, A. J., & de Boer, H. C. (2022). Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity. Journal of Thrombosis and Haemostasis, 20(4), 996-1007. https://doi.org/10.1111/jth.15642
    • Dauwerse, S., ten Cate, H., Spronk, H. M. H., & Nagy, M. (2022). The Composition and Physical Properties of Clots in COVID-19 Pathology. Diagnostics, 12(3), [580]. https://doi.org/10.3390/diagnostics12030580
    • Grover, S. P., Coughlin, T., Fleifil, S. M., Posma, J. J. N., Spronk, H. H. M., Heitmeier, S., Owens, A. P., & Mackman, N. (2022). Effect of combining aspirin and rivaroxaban on atherosclerosis in mice. Atherosclerosis, 345, 7-14. https://doi.org/10.1016/j.atherosclerosis.2022.02.010
    • Panova-Noeva, M., Wagner, B., Nagler, M., Koeck, T., Ten Cate, V., Eggebrecht, L., Prochaska, J. H., Meyer, I., Gerdes, C., Spronk, H. M., Lackner, K. J., Ten Cate, H., Leineweber, K., Heitmeier, S., Konstantinides, S., & Wild, P. S. (2022). Variation of platelet function in clinical phenotypes of acute venous thromboembolism - Results from the GMP-VTE project. Journal of Thrombosis and Haemostasis, 20(3), 705-715. https://doi.org/10.1111/jth.15595